Analytical Data
-
Gene name
IDO-1
- Application
-
Alternative Names
CD107B; INDO; Indoleamine-Pyrrole 2,3 Dioxygenase
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P14902
-
Expression Region
Ala2~Gly403
-
Molecular Weight
43kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IDO-1 (Indoleamine 2,3-dioxygenase 1) is an enzyme involved in the catabolism of tryptophan, an essential amino acid, into kynurenine. It plays a critical role in immune regulation and has garnered significant attention in cancer research, as it is often upregulated in tumors, contributing to immune evasion by suppressing T cell activity and promoting regulatory T cell (Treg) generation. The overexpression of IDO-1 in various tumor types, including melanoma, lung cancer, and breast cancer, has been linked to poor prognosis, indicating its potential as a therapeutic target. The enzyme's activity not only affects tumor microenvironments but also has implications in other pathologies, such as autoimmune diseases, infections, and neurodegenerative disorders. Researchers are investigating IDO-1 inhibitors as part of cancer immunotherapy strategies aimed at reinvigorating T cell responses and improving the effectiveness of existing treatments, such as checkpoint inhibitors. Understanding the molecular mechanisms by which IDO-1 operates, as well as its interactions with other immune modulators, is crucial to developing novel therapeutic approaches. Additionally, IDO-1's role in altering systemic metabolism and influencing the microbiome further emphasizes the complexity of its function in health and disease. Given these factors, IDO-1 represents a promising candidate for targeted therapies, warranting ongoing research to elucidate its full potential in clinical applications.
